Subacromial decompression surgery for impingement syndrome: rapid health technology assessment

Elvsaas IKØ, Flatby AV, Hamidi V, Espeland AL
Record ID 32018001070
Norwegian
Original Title: Akromionreseksjon ved impingementsyndrom i skulder: forenklet metodevurdering
Authors' results and conclusions: - There was no clinically relevant difference between subacromial decompression surgery and conservative treatment for pain, function and health-related quality of life at one year follow-up. We have medium to low confidence in the result. - There was no difference in effect between subacromial decompression surgery and placebo surgery for pain, function and health-related quality of life at one year follow-up. We have high to medium confidence in the result. - Complications were rare and evenly distributed between the groups. No serious complications were recorded. - Subacromial decompression surgery is the most costly treatment alternative at about 37,000 Norwegian krone (NOK). Conservative treatment with physiotherapy alone and injections cost respectively about 13,600 and 13,200 NOK. - There is a substantial potential for cost savings in the treatment of patients with pure subacromial shoulder impingement. Potential cost savings per health region depends on the reduction in number of procedures. This is estimated to: Northern Norway between 6.2 and 13.1m, Central Norway between 7.0 and 11.3m, Western Norway between 0 and 6.9m and South-Eastern Norway between 0 and 10.6m NOK. This corresponds to between 13.2 and 41.8m NOK on the national level.
Details
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Rapid Review
Country: Norway
MeSH Terms
  • Shoulder Impingement Syndrome
  • Surgical Procedures, Operative
  • Costs and Cost Analysis
  • Decompression, Surgical
  • Shoulder Pain
Contact
Organisation Name: Norwegian Institute of Public Health
Contact Address: P.O. Box 222 Skoyen, N-0123, Oslo
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.